Drug intelligence / Profile preview

XZP-5955

Development stage: Phase 2
Lead developer: Xuanzhu Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

XZP-5955 is an orally available small molecule dual inhibitor targeting the receptor tyrosine kinase c-ros oncogene 1 (ROS1) and tropomyosin-related kinase (TRK) family proteins. It is being developed for the treatment of patients with locally advanced or metastatic solid tumors harboring NTRK or ROS1 gene fusions, including non-small cell lung cancer. The drug acts by inhibiting both TRK and ROS1 signaling pathways that are implicated in tumor growth and survival. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics, and efficacy in these patient populations[1][2][3][4][5].

Targets

Trk (Trk receptor family)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)

Beyond the preview

Go deeper on XZP-5955.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XZP-5955.

Explore the full profile